Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation (NASDAQ: CELG):

“Our expanding portfolio of innovative therapies in oncology and immune-inflammatory diseases further positions us for sustained growth and value creation in the near and long term.”

2010 Third Quarter Financial Results Year-Over-Year

• Non-GAAP Total Revenue Increased 31 Percent to $908 Million; GAAP Total Revenue $910 Million
• Global REVLIMID Net Product Sales Increased 43 Percent to $641 Million
• Global VIDAZA Net Product Sales Increased 37 Percent to $141 Million
• Global THALOMID^® Net Product Sales of $94 Million
• Non-GAAP Operating Income Increased 40 Percent to $409 Million; GAAP Operating Income $311 Million
• Non-GAAP Net Income Increased 35 Percent to $350 Million; GAAP Net Income $281 Million
• Non-GAAP Diluted Earnings Per Share Increased 34 Percent to $0.75; GAAP Diluted Earnings Per Share $0.60

2010 Financial Outlook Update (Includes Impact of Acquisition of Abraxis BioScience)

• Total Revenue Expected to Increase Approximately 34 Percent Year-Over-Year to Approximately $3.60 Billion, Up From a Previous Range of $3.40 to $3.45 Billion
• REVLIMID Net Product Sales Anticipated to Increase Approximately 44 Percent Year-Over-Year to Approximately $2.45 Billion, Up From a Previous Range of $2.30 to $2.35 Billion
• Non-GAAP Diluted Earnings Per Share Expected to Increase Approximately 34 Percent Year-Over-Year to a Range of $2.78 to $2.80, Up From a Previous Range of $2.65 to $2.70

Recent Developments and Highlights

• Completed Acquisition of Abraxis BioScience
• Completed $1.25 Billion Debut Debt Offering
• Announced Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer
• Initiated Launch of REVLIMID^® in Japan for Treatment of Relapsed/Refractory Multiple Myeloma
• Initiated PALACE 1, PALACE 2, and PALACE 3, Phase III Trials Evaluating Apremilast in Psoriatic Arthritis, and ESTEEM 1, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis
• Brought Infringement Action to Enforce our REVLIMID Patents Against Natco Pharma Ltd. for Filing an Abbreviated New Drug Application With a Paragraph IV Certification for Lenalidomide
• ABRAXANE^® Pharmaceutical Composition and Method Claims Patent Issued on October 26, 2010, expiring in 2024
• Initiated MF-002, a Phase III Trial Evaluating Pomalidomide in Myelofibrosis
• Initiated AZA-AML-001, a Phase III Trial Evaluating VIDAZA^® in Newly Diagnosed Acute Myeloid Leukemia
• Initiated Phase II Trial for PDA-001 Cellular Therapy in Crohn's Disease

2010 Selected Corporate Objectives

• Expand Celgene Product Approvals, Reimbursements, and Global Market Share
• Submit REVLIMID Newly Diagnosed Multiple Myeloma (NDMM) Regulatory Filing with European Medicines Agency
• Complete Enrollment of MM-020, a Phase III Trial Evaluating REVLIMID and Low-Dose Dexamethasone Versus Melphalan, Prednisone, and Thalidomide in NDMM
• Submit ISTODAX^® Peripheral T-cell Lymphoma Regulatory Filing with Food and Drug Administration
• Advance More Than 25 Phase III and Pivotal Clinical Trials and 17 Preclinical Programs Addressing More Than 30 Serious and Debilitating Diseases
• Initiate ESTEEM 2, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis, and PALACE 4, a Phase III Trial Evaluating Apremilast in Psoriatic Arthritis
• Initiate Phase II Trial for Apremilast in Rheumatoid Arthritis
• Initiate Phase II Trial for PDA-001 Cellular Therapy in Ischemic Stroke; Initiate Phase I Trial in Multiple Sclerosis
• Initiate Phase II Trial for JNK CC-930 in Idiopathic Pulmonary Fibrosis and Discoid Lupus Erythematosus

Celgene Corporation (NASDAQ: CELG) announced non-GAAP (Generally Accepted Accounting Principles) net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010. Non-GAAP net income for the third quarter of 2009 was $259.8 million or non-GAAP diluted earnings per share of $0.56. Based on U.S. GAAP, Celgene reported net income of $281.2 million, or diluted earnings per share of $0.60 for the quarter ended September 30, 2010. GAAP net income for the third quarter of 2009 was $216.8 million, or diluted earnings per share of $0.46.

Celgene posted non-GAAP net income of $967.7 million or non-GAAP diluted earnings per share of $2.07 during the first nine months of 2010 as compared to non-GAAP net income of $681.0 million and non-GAAP diluted earnings per share of $1.46 in 2009. On a GAAP basis, Celgene reported net income of $670.9 million, or diluted earnings per share of $1.44 for the first nine months of 2010, compared to GAAP net income of $522.5 million, or diluted earnings per share of $1.12 in 2009.

"Our third quarter results reflect outstanding operational execution by our global team," said Bob Hugin, Celgene's Chief Executive Officer. "Our expanding portfolio of innovative therapies in oncology and immune-inflammatory diseases further positions us for sustained growth and value creation in the near and long term."

Product Sales Performance

Non-GAAP total revenue was a record $908.1 million for the quarter ended September 30, 2010, an increase of 31 percent from 2009. GAAP total revenue was $910.1 million for the quarter ended September 30, 2010. The increase in total revenue was driven by global market share gains and increased duration of therapy of REVLIMID^® and VIDAZA^®. Net sales of REVLIMID were $641.3 million, an increase of 43 percent over the same period in 2009. VIDAZA^® net sales were $141.4 million, an increase of 37 percent from 2009. Global THALOMID^® (inclusive of Thalidomide Celgene^® and Thalidomide Pharmion^®) sales were $94.2 million, a 14 percent decrease from 2009. Revenue from Focalin^® and the Ritalin^® family of drugs totaled $22.6 million for the third quarter of 2010 compared to $25.8 million over the same period in 2009.

For the first nine months of 2010, non-GAAP total revenue was a record $2.547 billion, an increase of 33 percent year-over-year. GAAP total revenue was $2.554 billion for the nine months ended September 30, 2010. REVLIMID net sales for the first nine months of 2010 were $1.759 billion, an increase of 45 percent over $1.209 billion for the same period in 2009. VIDAZA net sales for the first nine months of 2010 were $393.6 million, an increase of 46 percent over the same period in 2009. THALOMID net sales for the first nine months of 2010 were $296.0 million, a decrease of 10 percent from the same period in 2009. Revenue from Focalin and the Ritalin family of drugs totaled $79.3 million for the first nine months of 2010, an increase of 3 percent over the same period in 2009.

Research and Development

For the third quarter of 2010, non-GAAP R&D expenses, which exclude upfront collaboration payments and share-based employee compensation expense, were $232.3 million compared to $178.2 million for the third quarter of 2009. These R&D expenditures continue to support ongoing clinical progress in multiple proprietary development programs for REVLIMID, pomalidomide, and other compounds; VIDAZA; ISTODAX^®; amrubicin; apremilast and our oral anti-inflammatory compounds; our kinase inhibitor programs; our activin inhibitor program with ACE-011; and cellular therapy programs. On a GAAP basis, R&D expenses were $253.5 million for the third quarter of 2010 and $193.4 million in the same period in 2009.

Selling, General, and Administrative

Non-GAAP selling, general and administrative expenses, which exclude share-based employee compensation expense, were $204.1 million for the third quarter of 2010 compared to $172.3 million for the third quarter of 2009. The increase was primarily due to higher marketing and sales related expenses resulting from ongoing product launch activities of VIDAZA in Europe and ISTODAX in the United States as well as higher facilities costs. On a GAAP basis, selling, general and administrative expenses were $228.3 million for the third quarter of 2010 and $192.5 million in the same period in 2009.

Interest and Other Income, Net

For the quarter ended September 30, 2010, interest and other income, net, decreased to $20.8 million compared to $34.9 million in the same period in 2009. The decrease was primarily due to a reduction in interest and investment income as well as a decrease in net hedging and foreign currency revaluation gains in the quarter ended September 30, 2010, compared to the same period in 2009.

Cash, Cash Equivalents, and Marketable Securities

Celgene reported $3.530 billion in cash, cash equivalents, and marketable securities as of September 30, 2010.